Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text

Medicine, Oncology, Pharmacology +15

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye et al. · Journal of Clinical Oncology · 2010 · 404 citations

Medicine, Gynecology, Oncology +16

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

G. Blackledge, F. Lawton, C. W. E. Redman et al. · British Journal of Cancer · 1989 · 260 citations · Full text

Medicine, Gynecology, Oncology +17

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Andrés Poveda, Ignace Vergote, Sergei Tjulandin et al. · Annals of Oncology · 2010 · 168 citations · Full text

Medicine, Oncology, Pharmacology +15

Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails

Cristiana Sessa, Filippo de Braud, Antonella Perotti et al. · Journal of Clinical Oncology · 2005 · 164 citations

Medicine, Oncology, Pharmacology +17